MAPT and Alzheimer disease: We observed that STZ-ICV administration induced sporadic AD-like changes, including significant cognitive impairment as well as substantial neuronal loss, tau pathology, glucose hypometabolism, and microgliosis in the cortex and hippocampus of rats.